| Merkel cell carcinoma

Keytruda vs Zynyz

Side-by-side clinical, coverage, and cost comparison for merkel cell carcinoma.

Deep comparison between: Keytruda vs Zynyz with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZynyz has a higher rate of injection site reactions vs Keytruda based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zynyz but not Keytruda, including UnitedHealthcare

Category

Keytruda

Zynyz

At A Glance

RouteIV infusion

FrequencyEvery 3 weeks or Every 6 weeks

ClassPD-1 inhibitor

RouteIntravenous infusion

FrequencyEvery 3 or 4 weeks

ClassPD-1 blocking antibody

Indications

melanoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of the head and neck
Classic Hodgkin Lymphoma
Mediastinal (Thymic) Large B-Cell Lymphoma
Urothelial Carcinoma
Colorectal Carcinoma
Stomach Carcinoma
Esophageal carcinoma
Cervix carcinoma
Liver carcinoma
Biliary Tract Cancer
Merkel cell carcinoma
Renal Cell Carcinoma
Endometrial Carcinoma
Triple-Negative Breast Carcinoma
Malignant neoplasm of ovary
Squamous cell carcinoma of skin

Primary squamous cell carcinoma of anal canal
Merkel cell carcinoma

Dosing

melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV

Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV

Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily

Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors

Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV

Primary squamous cell carcinoma of anal canal (Combination therapy) 500 mg every 4 weeks or 375 mg every 3 weeks in combination with carboplatin and paclitaxel until disease progression, unacceptable toxicity, or up to 12 months

Primary squamous cell carcinoma of anal canal (Monotherapy, platinum-refractory) 500 mg every 4 weeks or 375 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months

Merkel cell carcinoma 500 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months

Contraindications

—

Drug Interactions

189View drug interactions

26View drug interactions

Adverse Reactions

Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism

Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions

Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis

Most common (>=10%) with combination therapy Fatigue, peripheral neuropathy, nausea, alopecia, diarrhea, musculoskeletal pain, constipation, hemorrhage, rash, vomiting, decreased appetite, pruritus, abdominal pain

Most common (>=10%) with SCAC monotherapy Fatigue, musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite, constipation, abdominal pain, dyspnea, pyrexia, vomiting, cough, pruritus, hypothyroidism, headache, decreased weight

Most common (>=10%) in MCC Musculoskeletal pain, fatigue, pruritus, diarrhea, rash, pyrexia, nausea, constipation

Serious Sepsis, pulmonary embolism, diarrhea, vomiting, non-urinary tract infection, perineal pain, anemia, hemorrhage, arrhythmia, pneumonitis, immune-mediated adverse reactions

Pharmacology

Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.

Retifanlimab-dlwr is a PD-1 blocking antibody that binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity to restore immune surveillance of tumors.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Keytruda